clinical trial · NCT04088409
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Eli Lilly and Company·phase3·active not recruiting·n = 30
UveitisBaricitinibAdalimumab
brief summary
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.
started
Oct 16, 2019
primary completion
Jul 17, 2023
completion
Jul 1, 2028
last updated
Apr 24, 2026
official title
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol